Grand River Aseptic Manufacturing

Grand River Aseptic Manufacturing is a US-based, private CDMO focused exclusively on sterile injectable fill-finish. Founded in 2005 and headquartered in Grand Rapids, Michigan, the company has established itself as a specialized partner for complex biologics, small molecules, and vaccines, having produced over 100 million COVID-19 vaccine doses. GRAM differentiates itself through strategic drug delivery partnerships, a flexible low-to-high volume production model, and a recent Phase II expansion adding new filling lines to increase capacity. Its business model is service-based, generating revenue through contract manufacturing.

Integrated aseptic fill-finish platform for liquid and lyophilized injectables in vials, syringes, and cartridges, with specialized capabilities for integration with autoinjectors and other drug delivery devices.

GRAM competes in the sterile fill-finish CDMO space against large, global players (e.g., Catalent, Lonza, Baxter) and other specialized, regional CDMOs. Its differentiation lies in its exclusive focus on fill-finish, strategic drug delivery device partnerships, and flexible low-to-high volume model from a US-based site.